SOA101 / Shine-On Biomedical - LARVOL DELTA

A phase I/IIa dose-escalation, dose-optimization, and dose-expansion study to evaluate the safety and preliminary efficacy of tri-specific antibody (SOA101) in subjects with advanced solid tumors. (ASCO 2026) - P1/2 | "Cohort 1 has been completed without DLT, and enrollment for Cohort 2 has begun following approval by the independent Safety Review Committee. Clinical Trial Registry Number: NCT07055594."

Clinical • First-in-human • IO biomarker • Metastases • P1/2 data • Trispecific • Breast Cancer • Colorectal Cancer • Head and Neck Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Solid Tumor • HLA-G

NbTAST-01: A Study to Investigate Safety and Preliminary Efficacy of SOA101 in Adult Subjects With Advanced Solid Tumors (clinicaltrials.gov) - P1/2 | N=76 | Recruiting | Sponsor: Shine-On Biomedical Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Solid Tumor

NbTAST-01: A Study to Investigate Safety and Preliminary Efficacy of SOA101 in Adult Subjects With Advanced Solid Tumors (clinicaltrials.gov) - P1/2 | N=76 | Not yet recruiting | Sponsor: Shine-On Biomedical Co., Ltd.

New P1/2 trial • Solid Tumor

China Medical University and Healthcare System Pioneers AI-Driven Drug Discovery and Allogeneic CAR-T Therapy: A Groundbreaking Leap in Cancer Treatment (PRNewswire) - "CMU and Healthcare System revealed the world's first allogeneic CAR-T therapy for solid cancers, developed by Ever Supreme Bio Technology. This therapy has demonstrated an unprecedented tumor reduction rate of over 90% in pre-clinical studies. Human clinical trials are underway, with FDA approval marking a pivotal moment in solid tumor treatment...Their innovations include: SOA101 Trispecific Antibody: A nanobody-based platform combining two immune checkpoint inhibitors, now in FDA-reviewed Phase I/IIa trials for cancer therapy; SOB100 HLA-G Targeted Exosome: Delivering drugs with pinpoint precision to tumors, this platform enhances efficacy while minimizing side effects...Human clinical trials for these technologies are set to begin in 2025..."

New trial • Preclinical • Solid Tumor